Hepatitis C News and Research

Latest Hepatitis C News and Research

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

China Biologic Products' fourth quarter revenue rises 185.6%

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for the fourth quarter and year ended December 31, 2009.

24 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Walgreens today announced earnings and sales for the second quarter of fiscal year 2010.

23 Mar 2010

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2009 and provided an update on various corporate developments.

23 Mar 2010

Atomic layer deposition technique for incorporating "biological functionality" into complex nanomaterials

A team led by researchers from North Carolina State University has published a paper that describes the use of a technique called atomic layer deposition to incorporate "biological functionality" into complex nanomaterials, which could lead to a new generation of medical and environmental health applications. For example, the researchers show how the technology can be used to develop effective, low-cost water purification devices that could be used in developing countries.

23 Mar 2010

Coalition of international health organizations oppose compensation for bone marrow donors

Voicing concern about the potential impact on patient and donor safety, nine leading international health organizations have formed a coalition to oppose compensating people who provide bone marrow for transplantation.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Researchers develop new compound to inhibit HIV transmission

A compound that can inhibit the transfer of HIV from one cell to another has been developed by researchers at the Institut de Biologie Structurale Jean-Pierre Ebel.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Study: Older adults with chronic illness often struggle to manage several prescribed drugs at a time

People with chronic illness often struggle to manage several prescribed drugs at a time. It's overwhelming when the vials, bottles and inhalers bulge from your medicine cabinet and you're confused about which drug is which, or when to take what.

20 Mar 2010

SHEA, APIC awarded first Partnership in Prevention Award to National Guard Health Affairs in Saudi Arabia

During the Fifth Decennial International Conference on Healthcare-Associated Infections, the Society for Healthcare Epidemiology of America and the Association for Professionals in Infection Control and Epidemiology awarded their first Partnership in Prevention Award to the National Guard Health Affairs in Saudi Arabia.

20 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Disease (NIAID) branch of the National Institutes of Health (NIH) for the further study and characterization of a back-up series of compounds related to its novel antibacterial, ACH-702.

18 Mar 2010

MediCare International offers insurance for all nationalities

The Lebanon is an important centre for international workers - Post conflict international health cover hard to arrange - Good hospital facilities can only be accessed with the right cover - MediCare International offers insurance for all nationalities

18 Mar 2010

Cangene receives European Commission approval to market ImmunoGam

Cangene Corporation today reports that it has received European Commission approval to market Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin), indicated for immunoprophylaxis of hepatitis B.

18 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

China Biologic Products' fourth quarter revenue rises 185.6%

EMA validates InterMune's pirfenidone MAA for IPF

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Atomic layer deposition technique for incorporating "biological functionality" into complex nanomaterials

Coalition of international health organizations oppose compensation for bone marrow donors

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Researchers develop new compound to inhibit HIV transmission

AARDA launches campaign on family AQ

Study: Older adults with chronic illness often struggle to manage several prescribed drugs at a time

SHEA, APIC awarded first Partnership in Prevention Award to National Guard Health Affairs in Saudi Arabia

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

MediCare International offers insurance for all nationalities

Cangene receives European Commission approval to market ImmunoGam

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in